Enterprise Value

-29.79M

Cash

119.1M

Avg Qtr Burn

-19.58M

Short % of Float

9.71%

Insider Ownership

2.78%

Institutional Own.

95.84%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ATI-1777 (JAK 1/3 inhibitor) Details
Atopic dermatitis, Skin disease/disorder

Phase 2b

Update

Phase 2a

Update

ATI-2138 (ITK/JAK3 inhibitor) Details
Autoimmune disease, Ulcerative colitis

Phase 2a

Initiation

ATI-2231 (MK2 inhibitor) Details
Solid tumor/s, Metastatic breast cancer, Pancreatic cancer, Cancer

Phase 1a

Update

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued